Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:31:35.167Z.
Consensus retrieved: 2026-10-06T10:52:13.440Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:31:35.167Z.
Quote observation: 2026-10-06T17:30:11.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6dae1ed753b385efcb651dd8f32a10b6f9886011747f410ddce9f57bee9a14c9
Forward PE Ratio (N/A) = Dated Quote Price ($83.32) / Consensus Forward EPS ($-3.79)
FORWARD PE RATIO
N/A
Dianthus Therapeutics, Inc.
Market Cap
$4.66B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | $4.66B | N/A |
| Option Care Health, Inc. (OPCH)vs › | $4.66B | 16.54 |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.65B | N/A |
| BillionToOne, Inc. (BLLN)vs › | $4.67B | 127.91 |
| LifeStance Health Group, Inc. (LFST)vs › | $4.68B | 75.22 |
| Oruka Therapeutics, Inc. (ORKA)vs › | $4.77B | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.78B | N/A |
| Heartflow, Inc. Common Stock (HTFL)vs › | $4.44B | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.40B | N/A |
| Indivior Pharmaceuticals Inc (INDV)vs › | $4.39B | 8.33 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $83.32, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-3.79 | $-4.08 – $-3.64 | 11 | n/m |
| 2027-12-31 | $-4.57 | $-5.57 – $-3.93 | 11 | n/m |
| 2028-12-31 | $-5.62 | $-7.81 – $-3.07 | 12 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
